Skip to main content
. 2013 Mar 5;8(3):e58438. doi: 10.1371/journal.pone.0058438

Table 1. Subject baseline characteristics.

Characteristic Placebo (n = 14) CDP323 100 mg bid (n = 14) CDP323 500 mg bid (n = 15) CDP323 1000 mg qd (n = 14) CDP323 1000 mg bid (n = 14) Overall (N = 71)
Age, mean, y (range) 45.5 (25.5–60.1) 46.4 (36.3–62.3) 46.0 (27.4–59.0) 45.4 (24.8–59.7) 47.2 (41.3–53.9) 46.1 (24.8–62.3)
Female, n (%) 6 (42.9) 7 (50.0) 12 (80.0) 8 (57.1) 11 (78.6) 44 (62.0)
Caucasian, n (%) 13 (92.9) 14 (100) 13 (86.7) 12 (85.7) 14 (100) 66 (93.0)
BMI, mean (range) 27.7 (18.1–38.0) 28.4 (21.2–43.3) 28.1 (21.6–39.9) 27.9 (20.4–45.2) 28.5 (18.3–45.0) 28.1 (18.1–45.2)
Creatinine clearance, mean,mL/min (range)a 134.1 (79–212) 114.5 (79–227) 113.9 (86–192) 126.6 (78–222) 121.9 (75–231) 122.2 (75–231)
Type of MS, n (%)
Relapsing remitting 11 (78.6) 10 (71.4) 11 (73.3) 8 (57.1) 10 (71.4) 50 (70.4)
Secondary progressive 3 (21.4) 4 (28.6) 4 (26.7) 6 (42.9) 4 (28.6) 21 (29.6)
EDSS
Mean (SD) 5.5 (1.5) 4.3 (1.7) 4.9 (1.6) 4.8 (1.8) 5.2 (1.7) 4.9 (1.7)
Median (range) 6.0 (1.5–6.5) 4.8 (2.0–6.5) 6.0 (2.0–6.5) 5.8 (2.0–6.5) 6.0 (1.0–6.5) 6.0 (1.0–6.5)
Relapses in last 12 months
Mean (SD) 1.6 (1.9) 1.1 (0.9) 1.1 (0.8) 1.6 (1.0) 1.1 (0.9) 1.3 (1.2)
Median (range)b 1.0 (0–8) 1.0 (0–3) 1.0 (0–3) 1.0 (0–3) 1.0 (0–3) 1.0 (0–8)
a

Determined by Cockroft formula: males = [(140 − age)×body weight]/[72×serum creatinine (mg/dL)]; females = [(140 − age)×body weight]/[72×serum creatinine (mg/dL)]×0.85.

b

Although 12 subjects had not experienced a relapse in the previous 12 months (4 in the 1000-mg bid group, 3 in each of the 100-mg bid and 500-mg bid groups, and 1 in each of the 1000-mg qd and placebo groups), they all fulfilled the inclusion criteria of having had at least one relapse in the previous 24 months.

bid = twice daily; BMI = body mass index; EDSS = Expanded Disability Status Scale; qd = once daily; SD = standard deviation.